PARP1 and cancer: Given their current exploration as therapeutic targets across diverse conditions, including cancer, metabolic disorders, and neurodegenerative models, an in-depth investigation of the mutual pathways they navigate holds significant promise for enhanced understanding of the SIRT1/PARP1 axis [35].